Financial impact of alternative approaches to reduce bacterial contamination of platelet transfusions
- 8 January 2019
- journal article
- research article
- Published by Wiley in Transfusion
- Vol. 59 (4), 1291-1299
- https://doi.org/10.1111/trf.15139
Abstract
BACKGROUND Bacterial contamination of platelets remains the leading infectious risk from blood transfusion. Pathogen reduction (PR), point‐of‐release testing (PORt), and secondary bacterial culture (SBC) have been proposed as alternative risk control strategies, but a comprehensive financial comparison has not been conducted. STUDY DESIGN AND METHODS A Markov‐based decision tree was constructed to model the financial and clinical impact of PR, PORt, and SBC, as well as a baseline strategy involving routine testing only. Hospitals were assumed to acquire leukoreduced apheresis platelets on Day 3 after collection, and, in the base case analysis, expiration would occur at the end of Day 5 (PR and SBC) or 7 (PORt). Monte Carlo simulations assessed the direct medical costs for platelet acquisition, testing, transfusion, and possible complications. Input parameters, including test sensitivity and specificity, were drawn from existing literature, and costs (2018 US dollars) were based on a hospital perspective. RESULTS The total costs per unit acquired by the hospital under the baseline strategy, PR, PORt, and SBC were $651.45, $827.82, $686.33, and $668.50, respectively. All risk‐reduction strategies decreased septic transfusion reactions and associated expenses, with the greatest reductions from PR. PR would add $191.09 in per‐unit acquisition costs, whereas PORt and SBC would increase per‐unit testing costs by $31.79 and $17.26, respectively. Financial outcomes were sensitive to platelet dating; allowing 7‐day storage with SBC would lead to a cost savings of $12.41 per transfused unit. Results remained robust in probabilistic sensitivity analyses. CONCLUSIONS All three strategies are viable approaches to reducing bacterially contaminated platelet transfusions, although SBC is likely to be the cheapest overall.Keywords
Funding Information
- National Institutes of Health (5R01AI120938 and 1R01AI128779)
This publication has 31 references indexed in Scilit:
- Using lean techniques to define the platelet (PLT) transfusion process and cost‐effectiveness to evaluate PLT dose transfusion strategiesTransfusion, 2012
- Bacterial contamination in platelets: incremental improvements drive down but do not eliminate riskTransfusion, 2011
- BLOOD COMPONENTS: Screening of single‐donor apheresis platelets for bacterial contamination: the PASSPORT study resultsTransfusion, 2010
- Proceedings of a Consensus Conference: Pathogen Inactivation—Making Decisions About New TechnologiesTransfusion Medicine Reviews, 2007
- The residual risk of sepsis: modeling the effect of concentration on bacterial detection in two‐bottle culture systems and an estimation of false‐negative culture ratesTransfusion, 2007
- Platelets: Testing, Dosing and the Storage Lesion—Recent AdvancesHematology, 2006
- Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT TrialBlood, 2004
- ORIGINAL PAPER. Relative values of the interventions of diversion and improved donor‐arm disinfection to reduce the bacterial risk from blood transfusionVox Sanguinis, 2004
- Transfusion‐transmitted bacterial infectionin the United States, 1998 through 2000Transfusion, 2001
- Bacterial sepsis secondary to platelet transfusion: an adverse effect of extended storage at room temperatureTransfusion, 1986